The biotechnology sector has seen increasing levels of investment and job creation in recent years, and has become an important sector for those charged with investment attraction. Cathy Mullan reports on the locations getting it right. 

Kaunas has established a reputation as a medical technology and R&D hub for the Baltic region. Its next step, as Natasha Turak discovers, is to ensure that its technological prowess is acknowledged on a global scale.

Lexington Medical’s expansion highlights its optimism about the wealth of expertise in the medical device industry in Massachusetts, as the locally incubated company opens a headquarters in the state. Natasha Turak reports.

Cologne's biotech centre BioCampus is branching out from its original purpose. Director André van Hall tells Natasha Turak why an interdisciplinary approach is the way forward.

Ute Berg, general manager of BioCampus Cologne and deputy mayor for economic development and real estate, explains to fDi how innovation and technology are vital for the future prosperity of the city.

Soaring costs at the US's major biotech hubs such as Boston and California are moving the spotlight to second-tier locations. But how can the likes of Philadelphia, Minneapolis and Maryland stand out from the crowd at attract investment in this lucrative sector? Michal Kaczmarski finds out.

The decision to move molecular diagnostics company Biocartis from Eindhoven to the small Belgian city of Mechelen could be viewed as a nostalgic one by the firm's Belgian founder, Rudi Pauwels. However, the location's tax incentives and grants have gone some way towards helping the firm to prepare for an international expansion. 

The Bio International Convention in Philadelphia attracted thousands of visitors from the world of biotech. Michal Kaczmarski spoke to representatives from a number of locations keen to catch the attention of would-be investors in this lucrative field to find out what makes their country stand out.

Thailand's expertise in the life sciences sector has long remained under the radar, with a lack of investment preventing many of the discoveries from its scientific community making it to the commercial stage. But a government entity, the Thailand Centre for Excellence for Life Sciences, is looking to change this.

Locations are taking advantage of the growing demand for healthcare, bringing together academia, big industry, start-ups, hospitals and sources of capital to create thriving specialised biomedical-pharmaceutical clusters.